MICROPORT's Subsidiary Enters Non-Binding Letter of Intent for Potential Sale of Orthopedic Business Stake to Tinavi Medical

Stock News07-15



MICROPORT (HKEX: 00853) has announced that on July 15, 2026, its subsidiary Suzhou MicroPort Orthopedics (Group) Co., Ltd. entered into a non-binding letter of intent with Tinavi Medical Technologies Co.,Ltd. (SHA: 688277). The letter outlines Tinavi's potential acquisition of a controlling equity stake in Shanghai MicroPort Orthopedics Medical Technology Co., Ltd. from Suzhou MicroPort and other shareholders of the target company. The consideration for the potential transaction is expected to be settled through the issuance of new shares by Tinavi.

Current Ownership and Target Business

As of the date of the letter of intent, the target company, which includes its subsidiaries, is 82.29%-owned by Suzhou MicroPort and is consolidated as a subsidiary of MICROPORT. It serves as the core operating entity for the group's international (non-China) orthopedic business. The target group primarily operates in overseas markets such as the United States, Japan, and Europe, focusing on hip and knee orthopedic reconstruction.

Product and Market Position

The target group has been established in the orthopedics field for many years, specializing in the research, production, and sale of innovative, clinically validated high-quality hip and knee joint products. It possesses a mature and scalable overseas sales network. Its flagship product, the Medial Pivot Knee System, boasts over 20 years of clinical application history. According to research published in The Knee journal, this knee system has demonstrated a cumulative 17-year implant survival rate of 98.8% and a patient satisfaction rate of 95%.

Strategic Rationale

The announcement highlighted that the target group owns a leading portfolio of joint implant products and a well-established marketing channel developed over years of serving overseas orthopedic markets. Tinavi, on the other hand, holds deep expertise and a leading position in orthopedic surgical robotics. The strategic and long-term objectives of both parties are highly aligned, and their businesses are complementary.

Potential Benefits

The potential transaction is expected to combine the strengths of both entities, creating synergies that exceed what could be achieved independently and supporting long-term performance growth. Through the potential deal, both parties aim to enhance the business scale, profitability, and risk resilience of Tinavi and the target group by integrating operations and gradually realizing synergistic benefits. This is anticipated to increase the long-term investment value of MICROPORT's stake in the target group's business.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment